Quinapril
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Quinapril: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Quinapril is an ACE inhibitor established for the treatment of hypertension (including its renovascular form) through inhibition of angiotensin II production. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests entirely on drug-class mechanistic reasoning rather than direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (ACE inhibitor class; no formal approved-indication text on file) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for quinapril is not currently available in this evidence pack (data gap DG002). Based on the information that is available, quinapril belongs to the ACE inhibitor (ACEi) class. This class works by inhibiting angiotensin-converting enzyme, reducing angiotensin II generation, and thereby lowering both systemic vascular resistance and intraglomerular pressure — the standard pharmacological basis for treating hypertension, including its renovascular form.
Malignant renovascular hypertension is a severe, accelerated-phase subtype of renovascular hypertension. Since ACE inhibitors are already an established class-level treatment for renovascular hypertension generally, extending this to the malignant subtype is mechanistically plausible as a class effect. However, this is an indirect, class-based inference rather than evidence specific to quinapril or to the "malignant" subtype.
No clinical trial or literature evidence in this evidence pack directly supports quinapril's use in malignant renovascular hypertension specifically. Malignant hypertension is also typically a medical emergency requiring acute, often intravenous, management — a context distinct from quinapril's standard oral chronic-use profile — which further limits how far the class-effect reasoning can be extended without dedicated data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
No authorizations on file. Quinapril is currently not marketed in New Zealand (0 licenses recorded).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/Medsafe package insert data for quinapril is currently unavailable — this is flagged as a Blocking data gap (DG001) that prevents a formal S1 safety evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score (99.86%), the top-ranked predicted indication (malignant renovascular hypertension) has zero supporting clinical trials or literature and rests only on generalized ACE-inhibitor class reasoning. Combined with a Blocking data gap on TFDA/Medsafe warnings and contraindications, the candidate cannot proceed past S0/S1 at this time.
To proceed, the following is needed:
- TFDA/Medsafe package insert (warnings, contraindications) to resolve DG001 and unblock S1 safety evaluation
- Detailed mechanism-of-action data from DrugBank to resolve DG002
- Targeted literature and clinical trial searches specific to quinapril in malignant/accelerated-phase renovascular hypertension (current searches returned 0 hits)
- Clarification of regulatory pathway, since quinapril has no current market authorization in New Zealand
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.